Physicians and researchers are warning that the surge in GLP-1 weight-loss medication use may exacerbate eating disorders, particularly among older populations. While roughly 10 million Americans are currently using these drugs, medical experts note that the widespread marketing of dramatic appetite suppression poses significant risks to those with histories of disordered eating.
Clinical Recognition Gaps in Aging Populations
A physician’s encounter with a 53-year-old patient highlights a growing trend: individuals seeking GLP-1s not for specific health goals, but due to pervasive advertising. When asked about her objectives, the patient replied, wp:inline: "I don’t really know," wp:inline: "But I keep seeing these ads, and everyone’s talking about it. I feel like maybe I should try it." According to AOL.com, a recent KFF poll found that one in eight American adults is currently taking a GLP-1 drug, with the highest usage reported in the 50-64 age group.
This demographic shift is concerning. Medical training has historically overlooked the nuances of disordered eating in older adults, often focusing on younger patients.
“This is hard to admit, but the truth is, we’re trained to miss eating disorders in older women.In medical school, the eating disorder cases we studied were almost always young white women. The textbooks showed underweight teenagers.
While medical textbooks often focus on underweight teenagers, research indicates that 13 percent of women over 50 exhibit symptoms of disordered eating. This rising number is compounded by the physiological changes of menopause, including metabolic shifts and uncontrollable body changes, which can trigger disordered eating behaviors.
The Link Between GLP-1s and Disordered Eating
The pharmaceutical promise of appetite control may act as a catalyst for those already struggling with food relationships. A 2024 study published in the International Journal of Eating Disorders found that GLP-1 medications could exacerbate or contribute to the development or treatment of an eating disorder. This risk is significant given that eating disorders affect more than 30 million people in the United States.
As the Washington Post reported, these drugs pose specific dangers to individuals with established conditions like anorexia. For those like Stevee Williams, who was diagnosed with anorexia at age 17, the struggle with food can persist throughout adulthood, making the introduction of powerful appetite suppressants a high-stakes medical decision.
Market Projections Amidst Pharmaceutical Shifts
The rise of GLP-1s has triggered a wave of anxiety within the retail sector, specifically regarding the longevity of the plus-size fashion market. Executives have expressed concerns about whether these medications will "kill" the market, a sentiment that some analysts suggest stems from a fundamental misunderstanding of the consumer base.
Despite the current pharmaceutical panic, historical data shows that the plus-size market has consistently grown alongside various diet trends. According to The Curvy Fashionista, the global plus-size clothing market is valued at $244.85 billion in 2025 and is projected to reach $395.60 billion by 2034. This growth suggests that the market’s resilience is tied to community and connection rather than just body size.
The Enduring Cycle of Diet Culture
The current fascination with GLP-1s is the latest chapter in a long history of weight-management trends, including the Atkins revolution, South Beach, and Keto. Since approximately 1987, every new promise of a "new body" has coincided with a growing market for plus-size consumers.
This cycle often reinforces a psychological pattern where the desire to eat leads to restriction, which in turn fuels further desire. The Nation reported that this food obsession can run deep in families, where individuals may feel they are approximately 30 percent fatter than they should be based on cultural standards, while others maintain extremely low body fat, such as 11 percent. The medication-driven focus on wp:inline: "eat less and slower" may simply be a modern iteration of an old, pervasive struggle.
As these medications become increasingly commonplace, the medical community remains focused on whether appetite suppression is being treated as a clinical solution or a cultural trend. Patients should consult their healthcare provider before beginning any new medication.
